Entrar/Registro  
HOME SPANISH
 
MediSan
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >MediSan >Year 2015, Issue 07


Rodulfo Gm, Fernández VF, González TMS, Pérez LR
Knowledge acquired by patients carriers of heart valve prosthesis on anticoagulation with sodium warfarin
MediSan 2015; 19 (07)

Language: Español
References: 16
Page: 839-844
PDF: 710.42 Kb.


Full text




ABSTRACT

A descriptive and cross-sectional study of 500 patients carriers of valve prosthesis who went to the outpatient department of the Cardiovascular Surgery Service from "Saturnino Lora Torres" Teaching Clinical Surgical Provincial Hospital from Santiago de Cuba was carried out during 2014 with the aim of evaluating their knowledge level on anticoagulation with sodium warfarin. The male sex (54,8 %), the age group 45-64 years (38,8 %) and those belonging to Santiago de Cuba and Holguín provinces (43,8 and 34,8 %, respectively) prevailed in the case material. Among the most remarkable characteristics there were: school level up to ninth grade (65,0 %), as well as those affected with mitral and aortic prosthesis almost in their totality. Although 40,2 % of the members of the series had more than 4 years of their surgical treatment, they didn't know the different alimentary, pharmacological interactions and time control criteria for prothrombine in the therapy of the oral anticoagulant.


Key words: valve prosthesis, cardiovascular surgery, anticoagulation, sodium warfarin, secondary health care.


REFERENCIAS

  1. Franco S. Enfermedad valvular cardiaca. Criterios para la selección de una prótesis cardiaca. 2 ed. Colombia: Editorial Colina; 2010. p. 434-40.

  2. Thourani VH, Weintraub WS, Craver JM, Jones EL, Mahoney EM, Guyton RA. Ten-Year trends in heart valve replacement operations. Ann Thorac Surg. 2000;70(2): 448-55.

  3. Ermis N, Atalay H, Altay H, Bilgi M, Binici S, Sezgin AT. Comparison of fibrinolytic versus surgical therapy in the treatment of obstructive prosthetic valve thrombosis: a single-center experience. Heart Surg Forum. 2011; 14(2):E87–E92.

  4. De la Cruz Avilés LE, Coll Muñoz Y, García Cuesta D. Comportamiento clínico y evolutivo de la disfunción valvular protésica. Experiencia de 5 años. Rev Cubana Cardiol Cir Cardiovasc. 2011; 17(4):311-6.

  5. Keuleers S, Herijgers P, Herregods MC, Budts W, Dubois C, Meuris B, et al. Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis. Am J Cardiol. 2011; 107(2):275–9.

  6. Pantaleón Bernal O, Salazar Sotolongo Y, Triana Mantilla ME, Aldama Figueroa A, Garrido Reyes MJ, Alonso Ríos M. Introducción del control terapéutico en el seguimiento de pacientes tratados con anticoagulantes orales. Rev Cubana Invest Bioméd. 2009 [citado 14 Ene 2013]; 28(1).

  7. De la Cruz Avilés L, Jorrín Román FR, Falcón Pérez E. Guía de práctica clínica para el tratamiento de la disfunción protésica valvular. MEDISUR. 2009; 7(1):145-50.

  8. Roudaut R, Lafitte S, Roudaut MF, Reant P, Pillois X, Durrieu-Jais C, et al. Management of prosthetic heart valve obstruction: fibrinolysis versus surgery. Early results and long-term follow-up in a single-centre study of 263 cases. Arch Cardiovasc Dis. 2009; 102(4):269–77.

  9. Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart. 2007; 93(1):137–42.

  10. Douglas AS. Historical aspects of anticoagulant therapy. Oxford England: Blackwell Scientific Publications; 1962. p. 1-7.

  11. Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost. 2011; 105:574-7.

  12. 12.Heiniger Mazo AI, Legaz Domench JM, Valpuesta Bermúdez MP, Sánchez-Lanuza Rodríguez M, Martínez Ballesteros M. Guía para el paciente anticoagulado. Sevilla: Servicio Andaluz de Salud; 2005.

  13. Llau JV, Ferrandis R, López Forte C. Antiagregantes y anticoagulantes: manejo del paciente quirúrgico anticoagulado. Cir Esp. 2009; 85 (Supl 1): 7-14.

  14. Consejería de Salud. Anticoagulación Oral. Coordinación en el control y seguimiento del paciente. Sevilla: Junta de Andalucía; 2005.

  15. Pernod G, Godiér A, Gozalo C, Tremey B, Sié P, French National Authority for Health. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res. 2010; 126(3):e167–74.

  16. Ansell J. Long-term patient self-management of oral anticoagulation. Arch Intern Med. 1995; 155: 2185-9.






>Journals >MediSan >Year 2015, Issue 07
 

· Journal Index 
· Links 






       
Copyright 2019